JP2013505008A - 患者が免疫療法に対するレスポンダーかそうでなきかを同定するための方法 - Google Patents

患者が免疫療法に対するレスポンダーかそうでなきかを同定するための方法 Download PDF

Info

Publication number
JP2013505008A
JP2013505008A JP2012529295A JP2012529295A JP2013505008A JP 2013505008 A JP2013505008 A JP 2013505008A JP 2012529295 A JP2012529295 A JP 2012529295A JP 2012529295 A JP2012529295 A JP 2012529295A JP 2013505008 A JP2013505008 A JP 2013505008A
Authority
JP
Japan
Prior art keywords
genes
gene
responder
patient
symbol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2012529295A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013505008A5 (enExample
Inventor
ブリシャール，ヴァンサン
ディジエ，バンジャマン，ジョルジュ，エリー，レア，ジスラン
グルセル，オリヴィエ
ルアヘド，ジャミラ
ウロア−モントヤ，フェルナンド
Original Assignee
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by グラクソスミスクライン バイオロジカルズ ソシエテ アノニム filed Critical グラクソスミスクライン バイオロジカルズ ソシエテ アノニム
Publication of JP2013505008A publication Critical patent/JP2013505008A/ja
Publication of JP2013505008A5 publication Critical patent/JP2013505008A5/ja
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
JP2012529295A 2009-09-18 2010-09-17 患者が免疫療法に対するレスポンダーかそうでなきかを同定するための方法 Ceased JP2013505008A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US27704609P 2009-09-18 2009-09-18
US61/277,046 2009-09-18
US27838709P 2009-10-06 2009-10-06
GBGB0917457.4A GB0917457D0 (en) 2009-10-06 2009-10-06 Method
US61/278,387 2009-10-06
GB0917457.4 2009-10-06
PCT/EP2010/063751 WO2011033095A1 (en) 2009-09-18 2010-09-17 Method for identifying whether a patient will be responder or not to immunotherapy

Publications (2)

Publication Number Publication Date
JP2013505008A true JP2013505008A (ja) 2013-02-14
JP2013505008A5 JP2013505008A5 (enExample) 2013-11-07

Family

ID=41393894

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012529295A Ceased JP2013505008A (ja) 2009-09-18 2010-09-17 患者が免疫療法に対するレスポンダーかそうでなきかを同定するための方法

Country Status (14)

Country Link
US (1) US20110070268A1 (enExample)
EP (1) EP2478116A1 (enExample)
JP (1) JP2013505008A (enExample)
KR (1) KR20130055553A (enExample)
CN (1) CN102597269A (enExample)
AU (1) AU2010297248A1 (enExample)
BR (1) BR112012006088A2 (enExample)
CA (1) CA2773666A1 (enExample)
EA (1) EA201290107A1 (enExample)
GB (1) GB0917457D0 (enExample)
IL (1) IL218313A0 (enExample)
MX (1) MX2012003329A (enExample)
SG (1) SG179129A1 (enExample)
WO (1) WO2011033095A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018503373A (ja) * 2014-12-30 2018-02-08 ジェネンテック， インコーポレイテッド がんの予後診断及び治療のための方法及び組成物
JP2024160217A (ja) * 2020-03-17 2024-11-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 治療に対するレスポンダを決定するための方法およびシステム

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2906523A1 (en) * 2013-03-15 2014-09-25 Myriad Genetics, Inc. Genes and gene signatures for diagnosis and treatment of melanoma
ES2946681T3 (es) 2014-07-02 2023-07-24 Myriad Mypath Llc Genes y firmas génicas para el diagnóstico y tratamiento del melanoma
KR20180126085A (ko) * 2016-05-05 2018-11-26 난토믹스, 엘엘씨 체크포인트 부전 및 그 방법(checkpoint failure and methods therefor)
KR102169901B1 (ko) * 2019-05-17 2020-10-26 연세대학교 산학협력단 Dna 메틸화를 이용한 면역 항암 요법의 치료 반응에 관한 정보 제공 방법 및 이를 이용한 키트
EP4161658A4 (en) * 2020-06-01 2024-10-02 Dana-Farber Cancer Institute, Inc. Methods for modulating mhc-i expression and immunotherapy uses thereof
CN115495026B (zh) * 2022-11-21 2023-03-10 杭州字节方舟科技有限公司 一种优化内存处理方法、装置、设备及存储介质

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007140958A2 (en) * 2006-06-02 2007-12-13 Glaxosmithkline Biologicals S.A. Method for identifying whether a patient will be responder or not to immunotherapy
WO2009068621A1 (en) * 2007-11-30 2009-06-04 Glaxosmithkline Biologicals S.A. Method for classifying cancer patients as responder or non-responder to immunotherapy

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
EP0671948B1 (en) 1992-06-25 1997-08-13 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccine composition containing adjuvants
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
JP3468773B2 (ja) 1994-07-15 2003-11-17 ザ ユニバーシティ オブ アイオワ リサーチ ファウンデーション 免疫調節オリゴヌクレオチド
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
CA2319309C (en) 1998-02-05 2010-08-10 Smithkline Beecham Biologicals S.A. Tumor-associated antigen derivatives from the mage family, and nucleic acid sequences encoding them, used for the preparation of fusion proteins and of compositions for vaccination
DE69929444T2 (de) 1998-08-10 2006-09-28 Antigenics Inc., Woburn Cpg-zusammensetzungen, saponin-adjuvantien und verfahren zu deren verwendung
CA2361009C (en) 1999-01-29 2012-10-23 Corixa Corporation Her-2/neu fusion proteins
CN100430478C (zh) 1999-03-11 2008-11-05 史密丝克莱恩比彻姆生物有限公司 Casb618多核苷酸和多肽及其用途
DK1187629T3 (da) 1999-04-19 2005-01-17 Glaxosmithkline Biolog Sa Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid
PL209127B1 (pl) 2000-02-23 2011-07-29 Smithkline Beecham Biolog Środek farmaceutyczny do stosowania w immunoterapeutycznym leczeniu raka i sposób diagnozowania u pacjenta obecności lub podatności na raka
US20020076469A1 (en) * 2000-10-31 2002-06-20 Colgate-Palmolive Company Composition and method
DE10127572A1 (de) * 2001-05-30 2002-12-05 Pathoarray Gmbh Werkzeuge zur Diagnostik, molekularen Definition und Therapieentwicklung chronischer entzündlicher Gelenkerkrankungen
US7229774B2 (en) * 2001-08-02 2007-06-12 Regents Of The University Of Michigan Expression profile of prostate cancer
WO2003050257A2 (en) * 2001-12-06 2003-06-19 University Of Florida Targeting leukemia cells
EP1482795B1 (en) 2002-02-04 2009-11-11 Corixa Corporation New immunoeffector compounds
US20040248151A1 (en) * 2002-04-05 2004-12-09 Ventana Medical Systems, Inc. Method for predicting the response to HER2-directed therapy
MXPA04012443A (es) 2002-06-11 2005-04-19 Glaxosmithkline Biolog Sa Composiciones inmunogenicas.
US20040231909A1 (en) * 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
WO2004076565A2 (en) * 2003-02-25 2004-09-10 Technical Knockout, Inc. Improved coated weight plates, dumbbells and method of manufacture
EP1605811A4 (en) * 2003-02-28 2008-06-11 Bayer Pharmaceuticals Corp EXPRESSION PROFILES FOR BREAST CANCER AND METHODS OF USE
US20050095607A1 (en) * 2003-03-07 2005-05-05 Arcturus Bioscience, Inc. University Of Louisville Breast cancer signatures
EP1608964A4 (en) 2003-03-14 2009-07-15 Peter Maccallum Cancer Inst CREATING AN EXPRESSION PROFILE OF TUMORS
US20040241725A1 (en) * 2003-03-25 2004-12-02 Wenming Xiao Lung cancer detection
US7598287B2 (en) * 2003-04-01 2009-10-06 Medical College Of Georgia Research Institute, Inc. Use of inhibitors of indoleamine-2,3-dioxygenase in combination with other therapeutic modalities
JP2007507222A (ja) * 2003-05-28 2007-03-29 ゲノミック ヘルス， インコーポレイテッド 化学療法に対する応答を予測するための遺伝子発現マーカー
EP2348110B1 (en) 2003-05-30 2013-03-27 OncoTherapy Science, Inc. Process for screening a drug response in cancer patients
EP1651775A2 (en) * 2003-06-18 2006-05-03 Arcturus Bioscience, Inc. Breast cancer survival and recurrence
EP1980629A3 (en) * 2003-08-28 2008-12-17 Ipsogen Identification of an erbb2 gene expression signature in breast cancers
WO2005032495A2 (en) * 2003-10-03 2005-04-14 Bayer Pharmaceuticals Corporation Gene expression profiles and methods of use
US20070110710A1 (en) * 2003-11-05 2007-05-17 New England Medical Center Hospitals, Inc. Treatment with immunoregulatory t cells
WO2005075680A1 (ja) * 2004-02-09 2005-08-18 Fuso Pharmaceutical Industries, Ltd. 核酸検出方法およびその利用
US20060195266A1 (en) 2005-02-25 2006-08-31 Yeatman Timothy J Methods for predicting cancer outcome and gene signatures for use therein
US20070237717A1 (en) * 2004-04-05 2007-10-11 Roland Martin Methods for Selection of Subjects for Multiple Sclerosis Therapy
US7332281B2 (en) * 2004-04-27 2008-02-19 Sagres Discovery, Inc. Therapeutic targets in cancer
WO2006054129A1 (en) 2004-11-19 2006-05-26 Institut Gustave Roussy Improved treatment of cancer by double-stranded rna
BRPI0518734A2 (pt) 2004-11-30 2008-12-02 Veridex Llc prognàstico de cÂncer de pulmço
US20070059720A9 (en) * 2004-12-06 2007-03-15 Suzanne Fuqua RNA expression profile predicting response to tamoxifen in breast cancer patients
US7666595B2 (en) 2005-02-25 2010-02-23 The Brigham And Women's Hospital, Inc. Biomarkers for predicting prostate cancer progression
GB0504302D0 (en) 2005-03-02 2005-04-06 Univ Dublin Markers for melanoma
EP1863930A2 (en) 2005-04-01 2007-12-12 NCC Technology Ventures Pte Limited Materials and methods relating to breast cancer classification
WO2006124836A1 (en) 2005-05-13 2006-11-23 Duke University Gene expression signatures for oncogenic pathway deregulation
US20070111257A1 (en) * 2005-07-07 2007-05-17 Kohne David E Improved protein expression comparison assay results and applications
JP5171812B2 (ja) * 2006-04-27 2013-03-27 ユニベルシテ ドゥ モントリオール 移植片対宿主病のリスクの評価および低減
WO2009034055A1 (en) * 2007-09-10 2009-03-19 Novartis Forschungsstiftung, Zweigniederlassung Method for predicting the response of a subject suffering from a viral infection of the liver to an antiviral therapy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007140958A2 (en) * 2006-06-02 2007-12-13 Glaxosmithkline Biologicals S.A. Method for identifying whether a patient will be responder or not to immunotherapy
WO2009068621A1 (en) * 2007-11-30 2009-06-04 Glaxosmithkline Biologicals S.A. Method for classifying cancer patients as responder or non-responder to immunotherapy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6014052800; Ｍｅｌａｎｏｍａ　Ｒｅｓｅａｒｃｈ ｖｏｌ．１３，　ｎｏ．４, 2003, ｐ．３７１-３７７ *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018503373A (ja) * 2014-12-30 2018-02-08 ジェネンテック， インコーポレイテッド がんの予後診断及び治療のための方法及び組成物
US11236394B2 (en) 2014-12-30 2022-02-01 Genentech, Inc. Methods and compositions for prognosis and treatment of cancers
US12385098B2 (en) 2014-12-30 2025-08-12 Genentech, Inc. Methods and compositions for prognosis and treatment of cancers
JP2024160217A (ja) * 2020-03-17 2024-11-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 治療に対するレスポンダを決定するための方法およびシステム

Also Published As

Publication number Publication date
EA201290107A1 (ru) 2012-10-30
AU2010297248A1 (en) 2012-04-12
CN102597269A (zh) 2012-07-18
KR20130055553A (ko) 2013-05-28
MX2012003329A (es) 2012-04-20
US20110070268A1 (en) 2011-03-24
BR112012006088A2 (pt) 2020-08-11
IL218313A0 (en) 2012-04-30
CA2773666A1 (en) 2011-03-24
GB0917457D0 (en) 2009-11-18
WO2011033095A1 (en) 2011-03-24
EP2478116A1 (en) 2012-07-25
SG179129A1 (en) 2012-05-30

Similar Documents

Publication Publication Date Title
US12139763B2 (en) Methods for subtyping of lung adenocarcinoma
US12139765B2 (en) Methods for subtyping of lung squamous cell carcinoma
JP2013505008A (ja) 患者が免疫療法に対するレスポンダーかそうでなきかを同定するための方法
BRPI0712497A2 (pt) perfil de gene, uso de um perfil, método para identificar um perfil, usos de uma sonda e de um kit de microarranjo para a identificação da expressão diferencial de pelo menos um produto de gene de ativação imune, microarranjo, kit de diagnóstico, e, método para tratar um paciente, e para induzir um perfil de gene respondedor em paciente distinguido como um não respondedor.
US20100247580A1 (en) Method for Classifying Cancer Patients as Responder or Non-Responder to Immunotherapy
KR101437718B1 (ko) 위암의 예후 예측용 마커 및 이를 이용하는 위암의 예후 예측 방법
EP2309273B1 (en) Novel tumor marker determination
CN101932723A (zh) 改进的对mage-a表达的检测
JP7034931B2 (ja) ネオエピトープのウイルス送達のための改善された組成物および方法ならびにその使用
JP2004505611A (ja) 乳癌の検出およびモニタリングのための方法、組成物、およびキット
JP2012005500A (ja) 食道癌、結腸癌、頭頸部癌、およびメラノーマにおけるマーカーの同定
CN102575284A (zh) 改进的基因表达检测
WO2007047847A2 (en) Methods for diagnosing cancer based on dna methylation status in nbl2
CN110573629B (zh) 用于诊断早期胰腺癌的方法和试剂盒
JP2013046630A (ja) Ｍａｇｅ−ａ３マーカーの特異的検出のためのプライマーおよびプローブを含む癌の検出および診断の方法
WO2023129460A2 (en) Tumor mhc class i expression is associated with interleukin-2 response in melanoma
US20100166783A1 (en) Method

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130913

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130913

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141216

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150310

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150615

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20151117

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20160322